Cargando…

Progress in mesenchymal stem cell–based therapy for acute liver failure

Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only cura...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yong-Hong, Wu, Dong-Bo, Chen, Bing, Chen, En-Qiang, Tang, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109312/
https://www.ncbi.nlm.nih.gov/pubmed/30143052
http://dx.doi.org/10.1186/s13287-018-0972-4
_version_ 1783350304689881088
author Wang, Yong-Hong
Wu, Dong-Bo
Chen, Bing
Chen, En-Qiang
Tang, Hong
author_facet Wang, Yong-Hong
Wu, Dong-Bo
Chen, Bing
Chen, En-Qiang
Tang, Hong
author_sort Wang, Yong-Hong
collection PubMed
description Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only curative treatment for acute liver failure is liver transplantation, but there are many restrictions on the application of liver transplantation. In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. Several types of stem cells have been used to study liver diseases; mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure.
format Online
Article
Text
id pubmed-6109312
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61093122018-08-29 Progress in mesenchymal stem cell–based therapy for acute liver failure Wang, Yong-Hong Wu, Dong-Bo Chen, Bing Chen, En-Qiang Tang, Hong Stem Cell Res Ther Review Acute liver failure is a life-threatening clinical syndrome characterized by rapid development of hepatocellular necrosis leading to high mortality and resource costs. Numerous treatment strategies for acute liver failure simply prevent complications and decelerate disease progression. The only curative treatment for acute liver failure is liver transplantation, but there are many restrictions on the application of liver transplantation. In recent years, a growing number of studies have shown that stem cells can effectively treat acute liver failure. Several types of stem cells have been used to study liver diseases; mesenchymal stem cells are most commonly used because they are easy to obtain and present no ethical problems. The aims of this article are to review the current knowledge regarding therapeutic mechanisms of mesenchymal stem cells in acute liver failure, to discuss recent advancements in preclinical and clinical studies in the treatment of mesenchymal stem cells, and to summarize the methodological improvement of mesenchymal stem cell transplantation in treating liver failure. BioMed Central 2018-08-24 /pmc/articles/PMC6109312/ /pubmed/30143052 http://dx.doi.org/10.1186/s13287-018-0972-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wang, Yong-Hong
Wu, Dong-Bo
Chen, Bing
Chen, En-Qiang
Tang, Hong
Progress in mesenchymal stem cell–based therapy for acute liver failure
title Progress in mesenchymal stem cell–based therapy for acute liver failure
title_full Progress in mesenchymal stem cell–based therapy for acute liver failure
title_fullStr Progress in mesenchymal stem cell–based therapy for acute liver failure
title_full_unstemmed Progress in mesenchymal stem cell–based therapy for acute liver failure
title_short Progress in mesenchymal stem cell–based therapy for acute liver failure
title_sort progress in mesenchymal stem cell–based therapy for acute liver failure
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109312/
https://www.ncbi.nlm.nih.gov/pubmed/30143052
http://dx.doi.org/10.1186/s13287-018-0972-4
work_keys_str_mv AT wangyonghong progressinmesenchymalstemcellbasedtherapyforacuteliverfailure
AT wudongbo progressinmesenchymalstemcellbasedtherapyforacuteliverfailure
AT chenbing progressinmesenchymalstemcellbasedtherapyforacuteliverfailure
AT chenenqiang progressinmesenchymalstemcellbasedtherapyforacuteliverfailure
AT tanghong progressinmesenchymalstemcellbasedtherapyforacuteliverfailure